NCT02082236View on ClinicalTrials.gov

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy
Interventions
DRUG

Treatment Arm A: Sufenta®

Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute

DRUG

Treatment B: Sufentanil SSM 30 mcg

single-dose SSM 30 mcg

DRUG

Treatment C: SSM 15 mcg

2 consecutive doses of SSM 15 mcg administered 20 minutes apart

DRUG

Treatment D: SSM 30 mcg

12 consecutive doses of SSM 30 mcg administered 1 hour apart

Trial Locations (1)

66219

PRA, Lenexa

All Listed Sponsors
lead

Talphera, Inc

INDUSTRY

NCT02082236 - Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects | Biotech Hunter | Biotech Hunter